ES2038359T3 - Procedimiento para la obtencion de formulaciones inyectables intramusculares de inhibidores de girasa. - Google Patents

Procedimiento para la obtencion de formulaciones inyectables intramusculares de inhibidores de girasa.

Info

Publication number
ES2038359T3
ES2038359T3 ES89105795T ES89105795T ES2038359T3 ES 2038359 T3 ES2038359 T3 ES 2038359T3 ES 89105795 T ES89105795 T ES 89105795T ES 89105795 T ES89105795 T ES 89105795T ES 2038359 T3 ES2038359 T3 ES 2038359T3
Authority
ES
Spain
Prior art keywords
girase
inhibitors
procedure
intramuscular injection
injection formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89105795T
Other languages
English (en)
Inventor
Norbert Dr Pollinger
Peter Dr Serno
Wolfram Dr Hofmann
Dieter Dr Beermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of ES2038359T3 publication Critical patent/ES2038359T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PATENTE AFECTA A INYECCIONES INTRAMUSCULARES QUE CONTIENEN COMO SUSTANCIA ACTIVA INHIBIDORES DE GIRASA DEL GRUPO DE LOS ACIDOS QUINOLONCARBOXILICO Y 1,8-NAFTIRIDON-3-CARBOXILICO, A SU FABRICACION Y A SU UTILIZACION COMO MEDICAMENTO.
ES89105795T 1988-04-15 1989-04-03 Procedimiento para la obtencion de formulaciones inyectables intramusculares de inhibidores de girasa. Expired - Lifetime ES2038359T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3812508 1988-04-15
DE3902079A DE3902079A1 (de) 1988-04-15 1989-01-25 I.m. injektionsformen von gyrase-inhibitoren

Publications (1)

Publication Number Publication Date
ES2038359T3 true ES2038359T3 (es) 1995-04-01

Family

ID=25866993

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89105795T Expired - Lifetime ES2038359T3 (es) 1988-04-15 1989-04-03 Procedimiento para la obtencion de formulaciones inyectables intramusculares de inhibidores de girasa.

Country Status (15)

Country Link
US (1) US5023257A (es)
EP (1) EP0337231B1 (es)
JP (1) JPH01316321A (es)
KR (1) KR900015736A (es)
CN (1) CN1037272A (es)
AU (1) AU610380B2 (es)
CA (1) CA1336822C (es)
DE (2) DE3902079A1 (es)
DK (1) DK169772B1 (es)
ES (1) ES2038359T3 (es)
GR (1) GR3005415T3 (es)
HU (1) HUT54048A (es)
IE (1) IE60407B1 (es)
IL (1) IL89928A (es)
NZ (1) NZ228708A (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2655545B1 (fr) * 1989-12-11 1994-06-10 Rhone Poulenc Sante Nouvelle application therapeutique des derives des fluoroquinolones.
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
US5420124A (en) * 1994-01-12 1995-05-30 Kim; Young S. Stable, painless piroxicam potassium injectable composition
PT782448E (pt) * 1995-06-06 2002-07-31 Bayer Ag Formulacoes oticas antibacterianas nao ototoxicas nao sensibilizantes nao irritantes
US5843930A (en) * 1995-06-06 1998-12-01 Bayer Corporation Method of treating otitis with ciprofloxacin-hydrocortisone suspension
EP0868183B1 (en) * 1995-12-21 2002-01-30 Pfizer Inc. Injectable quinolone formulations
IN186245B (es) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
ID21415A (id) 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
AU2001232809A1 (en) * 2000-01-18 2001-07-31 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US20030170858A1 (en) * 2001-01-16 2003-09-11 Paul Charifson Gyrase inhibitors and uses thereof
WO2003077842A2 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company Palatable oral suspension and method
PL1666477T3 (pl) 2003-09-10 2013-11-29 Kyorin Seiyaku Kk Pochodna kwasu 7-(4-podstawionego-3-cyklopropyloaminometylo-1- pirolidynylo)chinolonokarboksylowego
US20070196398A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone fatty acid salt compositions
US8222407B2 (en) 2007-05-24 2012-07-17 Kyorin Pharmaceutical Co., Ltd. Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position
CN102716072B (zh) * 2012-06-13 2014-06-18 广州南新制药有限公司 一种乳酸环丙沙星氯化钠注射液的制备方法
US10429292B2 (en) 2013-03-15 2019-10-01 Iris International, Inc. Dynamic range extension systems and methods for particle analysis in blood samples
JP6523245B2 (ja) * 2013-03-15 2019-05-29 アイリス インターナショナル, インコーポレイテッド 血液試料における粒子分析のためのシース液システム及び方法
US9393243B1 (en) 2015-07-14 2016-07-19 Nilesh Parikh Topical Ciprofloxacin compositions
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE564864A (es) *
US4181721A (en) * 1975-10-27 1980-01-01 Schering Aktiengesellschaft Depot preparations in an oily, unsaturated solution for intramuscular injection
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
DE3033157A1 (de) * 1980-09-03 1982-04-01 Bayer Ag, 5090 Leverkusen 7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-naphthyridin-3-carbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
US4620007A (en) * 1980-09-03 1986-10-28 Bayer Aktiengesellschaft 6-fluoro-7-chloro-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
DE3306771A1 (de) * 1983-02-25 1984-08-30 Bayer Ag, 5090 Leverkusen Chinoloncarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
DE3306772A1 (de) * 1983-02-25 1984-08-30 Bayer Ag, 5090 Leverkusen Chinolonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
DE3324192A1 (de) * 1983-07-05 1985-01-17 Troponwerke Gmbh & Co Kg Depot-antiphlogistika
DE3333719A1 (de) * 1983-09-17 1985-04-04 Bayer Ag Loesungen milchsaurer salze von piperazinylchinolon- und piperazinyl-azachinoloncarbonsaeuren
DE3517709A1 (de) * 1985-01-05 1986-07-10 Bayer Ag Basische zubereitungen von chinoloncarbonsaeuren
DE3522406A1 (de) * 1985-06-22 1987-01-02 Bayer Ag Verfahren zur herstellung von 1,8-verbrueckten 4-chinolon-3-carbonsaeuren
DE3608745A1 (de) * 1985-07-24 1987-01-29 Bayer Ag Bakterizide zubereitungen zur anwendung auf dem gebiet der veterinaermedizin
US4816247A (en) * 1985-09-11 1989-03-28 American Cyanamid Company Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs
IN166416B (es) * 1985-09-18 1990-05-05 Pfizer
DE3537761A1 (de) * 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
DE3542972A1 (de) * 1985-12-05 1987-06-11 Merck Patent Gmbh Pharmakadepot
DE3705621C2 (de) * 1986-02-25 1997-01-09 Otsuka Pharma Co Ltd Heterocyclisch substituierte Chinoloncarbonsäurederivate
DE3623757A1 (de) * 1986-07-15 1988-01-21 Bayer Ag Neue 1,8-verbrueckte 4-chinoloncarbonsaeuren und diese enthaltende arzneimittel
IL80459A (en) * 1986-10-30 1991-04-15 Abic Ltd Water-soluble adduct of norfloxacin and nicotinic acid
DE3713672A1 (de) * 1987-04-24 1988-11-17 Bayer Ag Verfahren zur herstellung von parenteral verabreichbaren chinoloncarbonsaeuren
US4780468A (en) * 1987-08-07 1988-10-25 Warner-Lambert Company 8-trifluoromethyl quinolones as antibacterial agents
US4933335A (en) * 1987-08-07 1990-06-12 Warner-Lambert Company Quinolones as antibacterial agents
US4803205A (en) * 1987-08-07 1989-02-07 Warner-Lambert Company Quinolones as antibacterial agents
US4839355A (en) * 1987-09-09 1989-06-13 Sterling Drug Inc. Tricyclic-pyridinylquinoline compounds, their preparation and use

Also Published As

Publication number Publication date
CN1037272A (zh) 1989-11-22
NZ228708A (en) 1992-06-25
EP0337231B1 (de) 1992-06-17
EP0337231A3 (en) 1990-01-17
US5023257A (en) 1991-06-11
IE60407B1 (en) 1994-07-13
KR900015736A (ko) 1990-11-10
HUT54048A (en) 1991-01-28
EP0337231A2 (de) 1989-10-18
IE891201L (en) 1989-10-15
GR3005415T3 (es) 1993-05-24
DE58901663D1 (de) 1992-07-23
AU610380B2 (en) 1991-05-16
IL89928A0 (en) 1989-12-15
JPH01316321A (ja) 1989-12-21
CA1336822C (en) 1995-08-29
DE3902079A1 (de) 1989-10-26
DK169772B1 (da) 1995-02-27
DK181389A (da) 1989-10-31
AU3275389A (en) 1989-10-19
IL89928A (en) 1993-05-13
DK181389D0 (da) 1989-04-14

Similar Documents

Publication Publication Date Title
ES2038359T3 (es) Procedimiento para la obtencion de formulaciones inyectables intramusculares de inhibidores de girasa.
SE8403487L (sv) Farmaceutisk komposition
MX9203150A (es) Nuevos esteres de acidos tienilcarboxilicos de aminoalcoholes, sus productos de cuaternizacion y las composiciones farmaceuticas que los contienen.
ES2054860T3 (es) Nuevos derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion, asi como a su utilizacion como medicamentos.
IS3156A7 (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
AR030541A1 (es) Acidos aminopropilfosfinicos, su utilizacion para la manufactura de medicamentos, y formulacion farmaceutica
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
IT7831446A0 (it) Acidi omega-amminoalcanoil-omega-ammino-a lcanoici n-sostituiti, loro impiego e procedimenti per la loro preparazione e anche prodotti medicinali contenenti questi composti.
AR218981A1 (es) Composiciones para la regulacion del crecimiento de las plantas en base a derivados de acidos cicloalcanocarboxilicos,como sustancia activa;nuevos derivados de acidos cicloalcanocarboxilicos para esas composiciones,y procedimiento para producir dichos derivados
YU221889A (en) Process for producing new pharmaceutical mixture
ES2041705T3 (es) Procedimiento para la preparacion de 1-(4-hidroxi-3,5-di-terc-butil-benzoil)-homopiperazina y sus derivados.
ES2147629T3 (es) Guanidinas de acido alquenilcarboxilico sustituidas con un grupo fluorofenilo como inhibidores del intercambio de na+/nh+, su procedimiento de preparacion y su uso como medicamento o agente diagnostico asi como el medicamento que las contiene.
FR2361877A1 (fr) Nouvelles lactones d'acides libres du type prostaglandine, leur preparation et medicament les contenant
ES2102043T3 (es) Derivados de 22-en-25-oxa en la serie de la vitamina d, procedimiento para su preparacion, preparados farmaceuticos que los contienen, asi como su utilizacion en calidad de medicamentos.
ES2032582T3 (es) Procedimiento para preparar derivados de la oxima del 1,2,5,6,-tetrahidropiridin -3-carboxialdehido.
MX9301746A (es) Nuevos acidos 9-fluor-7-oxo-7h-pirido(1,2,3,-de)(1,4)-benzoxacin-6-carboxilicos y sus esteres, procedimiento para su preparacion y medicamentos que los contienen.
IT7827493A0 (it) Derivati di acidi amidinosolfonici, processo per la loro preparazione e composizioni farmaceutiche che contengono questi derivati.
ES2043696T3 (es) Derivados de prostaglandina e1 (derivados-pge1) como substancias activas farmaceuticas y medicamentos que contienen estos compuestos, especialmente para aplicacion transcutanea.
AR001769A1 (es) Benzamida enterocinética composiciones farmacéuticas que las contienen procedimiento para la preparación de dichas composiciones farmacéuticas el uso de dichos compuestos para la manufactura de medicamentos y un procedimiento para su preparación
ES2143833T3 (es) Acidos y esteres de la diosmetina y composiciones farmaceuticas que los contienen.
PT87737A (pt) Processo para a preparacao de composicoes farmaceuticas analgesicas contendo derivados de dioxopiperidina como substancia activa
MX9301608A (es) Acidos 7-oxo-7h-pirido(1,2,3,de)(1,4)benzoxacin-6-carboxilico y sus esteres, procedimiento para su preparacion y medicamentos que los contienen.
ES2058203T3 (es) Derivados del acido pirocatequincarboxilico, su obtencion y empleo como substancias activas para medicamentos.
ES556437A0 (es) Procedimiento para preparar un agente que contiene tirosina o un derivado de tirosina como sustancia activa para mejorar la fecundidad de mamiferos.
ES2122962T3 (es) Derivados de alquileno-dioxibenceno opticamente activos y su uso en terapia.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 337231

Country of ref document: ES